Titles
- Understanding coverage considerations for COVID-19 vaccines and treatments2
- 30-Day notices, 135-day premarket approval (PMA) supplements and 75-day humanitarian device exemption (HDE) supplements for manufacturing method or process changes: guidance for industry and Food and Drug Administration staff1
- 340B Drug Discount Program: oversight of the Intersection with the Medicaid Drug Rebate Program needs improvement : report to Congressional requesters1
- 510(k) third party review program: guidance for industry, Food and Drug Administration staff, and third party review organizations1
- A call for federal action to improve nursing facilities1
- A comparison of brand-name drug prices among selected federal programs1
- A few states fell short in timely investigation of the most serious nursing home complaints: 2011-20151
- A pathway to full integration of care for Medicare-Medicaid beneficiaries1
- A premium support system for Medicare: updated analysis of illustrative options1
- A public option for health insurance in the nongroup marketplaces: key design considerations and implications1
- A resource guide for using Medicare’s enrollment race and ethnicity data1
- A risk-based approach to monitoring of clinical investigations questions and answers: guidance for industry1
- A single-payer health care system that is based on Medicare’s fee-for-service program: testimony before the Committee on the Budget, United States Senate1
- A state roadmap1
- ACF cannot ensure that all child victims of abuse and neglect have court representation1
- ACF should improve oversight of head start to better protect children’s safety1
- ACOs' strategies for transitioning to value-based care: lessons from the Medicare shared savings program1
- ANDA submissions--amendments to abbreviated new drug applications under GDUFA1
- ANDA submissions: amendments and requests for final approval to tentatively approved ANDAs1
- ANDAs for certain highly purified synthetic peptide drug products that refer to listed drugs of rDNA origin1